Skip to content
PatientMatchFind trials
Study details
Enrolling now

VENTURI Trial

University of Alabama at Birmingham
NCT IDNCT07282886ClinicalTrials.gov data as of Apr 2026
Check if I qualifyBack to resultsClinicalTrials.gov
Phase

Phase 2

Target enrollment

20

Study length

about 5 years

Ages

18–75

Locations

1 site in AL

About this study

This trial is testing a treatment for asthma. It compares two different inhaler medications to see which one works best in people with uncontrolled asthma.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrrolate pMDI
  • 2.Take Fluticasone Furoate/Umeclidinium/Vilanterol 100 MCG/1 ACTUATION-62.5 MCG/1 ACTUATION-25 MCG/1 ACTUATION Inhalation Powder
PhasePhase 2
DrugBeclomethasone Dipropionate
Routeinhaled
Primary goalEvaluate the effect of extrafine beclomethasone dipropionate/formoterol fumarate /glycopyrrolate compared with non-extrafine fluticasone furoate/ umeclidinium/vilanterol on ventilation defect percentage utilizing 129Xenon MRI

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low10%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

Anti-inflammatory Agent (Corticosteroid Hormone Receptor Agonists), fluticasone furoate, Respiratory System Agent (Adrenergic beta2-Agonists), Central Nervous System Agent (Cholinergic Muscarinic Antagonists), Respiratory System Agent (Cholinergic Antagonists)

Drug routes

inhaled, topical (Topical Cream), oral (Oral Tablet)

Endpoints

Primary: Evaluate the effect of extrafine beclomethasone dipropionate/formoterol fumarate /glycopyrrolate compared with non-extrafine fluticasone furoate/ umeclidinium/vilanterol on ventilation defect percentage utilizing 129Xenon MRI.

Body systems

Respiratory

Check if I qualifyView on ClinicalTrials.gov